Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 43 | 2025 | 406 | 9.020 |
Why?
|
| Endometrial Neoplasms | 17 | 2023 | 79 | 5.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 10 | 2017 | 57 | 2.160 |
Why?
|
| Prospective Studies | 44 | 2025 | 1574 | 1.710 |
Why?
|
| Diet | 10 | 2022 | 810 | 1.700 |
Why?
|
| Reproductive History | 8 | 2025 | 27 | 1.650 |
Why?
|
| Cohort Studies | 32 | 2025 | 1729 | 1.630 |
Why?
|
| Risk Factors | 48 | 2025 | 3942 | 1.510 |
Why?
|
| Middle Aged | 66 | 2025 | 11819 | 1.490 |
Why?
|
| Female | 86 | 2025 | 24018 | 1.420 |
Why?
|
| Breast Neoplasms | 16 | 2024 | 1679 | 1.240 |
Why?
|
| Parity | 12 | 2024 | 60 | 1.230 |
Why?
|
| Receptors, Progesterone | 8 | 2021 | 90 | 1.210 |
Why?
|
| Case-Control Studies | 31 | 2024 | 1266 | 1.180 |
Why?
|
| Aged | 39 | 2025 | 7982 | 1.180 |
Why?
|
| Humans | 90 | 2025 | 42163 | 1.080 |
Why?
|
| Gonadal Steroid Hormones | 5 | 2021 | 53 | 1.050 |
Why?
|
| Insulin | 2 | 2021 | 255 | 1.030 |
Why?
|
| Adult | 48 | 2025 | 13458 | 0.990 |
Why?
|
| Dietary Fats | 3 | 2015 | 117 | 0.980 |
Why?
|
| Postmenopause | 5 | 2021 | 139 | 0.980 |
Why?
|
| Receptors, Estrogen | 7 | 2021 | 177 | 0.970 |
Why?
|
| Dairy Products | 2 | 2014 | 34 | 0.810 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 147 | 0.780 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 683 | 0.770 |
Why?
|
| Follow-Up Studies | 18 | 2025 | 1051 | 0.740 |
Why?
|
| Prognosis | 17 | 2025 | 850 | 0.740 |
Why?
|
| Proportional Hazards Models | 12 | 2024 | 512 | 0.730 |
Why?
|
| Menarche | 5 | 2024 | 15 | 0.710 |
Why?
|
| Parabens | 1 | 2021 | 9 | 0.710 |
Why?
|
| Europe | 19 | 2022 | 114 | 0.700 |
Why?
|
| Somatomedins | 1 | 2021 | 5 | 0.700 |
Why?
|
| Phthalic Acids | 1 | 2021 | 18 | 0.700 |
Why?
|
| Analgesics | 2 | 2018 | 55 | 0.700 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 25 | 0.700 |
Why?
|
| Gonadal Hormones | 1 | 2021 | 5 | 0.700 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 287 | 0.690 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 49 | 0.680 |
Why?
|
| Age Factors | 9 | 2025 | 1139 | 0.660 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2019 | 44 | 0.650 |
Why?
|
| Phenols | 1 | 2021 | 102 | 0.650 |
Why?
|
| Menopause | 9 | 2024 | 63 | 0.640 |
Why?
|
| Nutritional Status | 4 | 2021 | 115 | 0.620 |
Why?
|
| Aspirin | 2 | 2018 | 88 | 0.600 |
Why?
|
| Fatty Acids | 2 | 2020 | 134 | 0.600 |
Why?
|
| State Medicine | 1 | 2018 | 9 | 0.590 |
Why?
|
| Acetaminophen | 1 | 2018 | 28 | 0.580 |
Why?
|
| Ovary | 3 | 2019 | 112 | 0.570 |
Why?
|
| Contraceptives, Oral | 4 | 2024 | 17 | 0.560 |
Why?
|
| Feeding Behavior | 3 | 2015 | 461 | 0.540 |
Why?
|
| Asia | 7 | 2025 | 99 | 0.510 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 42 | 0.480 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2017 | 81 | 0.470 |
Why?
|
| Endometrium | 1 | 2016 | 60 | 0.470 |
Why?
|
| Life Style | 4 | 2024 | 326 | 0.460 |
Why?
|
| United States | 9 | 2024 | 5072 | 0.450 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2014 | 9 | 0.450 |
Why?
|
| Premenopause | 8 | 2018 | 109 | 0.440 |
Why?
|
| Risk | 8 | 2019 | 289 | 0.430 |
Why?
|
| Fallopian Tubes | 1 | 2013 | 19 | 0.420 |
Why?
|
| Body Mass Index | 7 | 2025 | 916 | 0.400 |
Why?
|
| Incidence | 10 | 2025 | 1054 | 0.390 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2012 | 2 | 0.390 |
Why?
|
| Talc | 2 | 2013 | 3 | 0.390 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2017 | 20 | 0.380 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2017 | 24 | 0.380 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 479 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 150 | 0.380 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1265 | 0.370 |
Why?
|
| Odds Ratio | 5 | 2024 | 587 | 0.360 |
Why?
|
| Risk Assessment | 5 | 2018 | 845 | 0.360 |
Why?
|
| Acrylamide | 3 | 2015 | 8 | 0.350 |
Why?
|
| Food | 1 | 2012 | 102 | 0.350 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 366 | 0.350 |
Why?
|
| Hysterectomy | 2 | 2025 | 39 | 0.330 |
Why?
|
| Pregnancy | 11 | 2024 | 1737 | 0.330 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 532 | 0.330 |
Why?
|
| Epithelial Cells | 1 | 2013 | 426 | 0.330 |
Why?
|
| Vitamin D | 1 | 2012 | 196 | 0.330 |
Why?
|
| Early Detection of Cancer | 4 | 2018 | 428 | 0.320 |
Why?
|
| CA-125 Antigen | 3 | 2018 | 11 | 0.320 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2017 | 5 | 0.310 |
Why?
|
| Iron, Dietary | 2 | 2018 | 13 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 165 | 0.290 |
Why?
|
| Retrospective Studies | 3 | 2024 | 2485 | 0.290 |
Why?
|
| Young Adult | 11 | 2025 | 4936 | 0.290 |
Why?
|
| Heme | 2 | 2018 | 72 | 0.280 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 573 | 0.280 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2008 | 19 | 0.280 |
Why?
|
| Logistic Models | 3 | 2024 | 1001 | 0.280 |
Why?
|
| Breast Feeding | 4 | 2018 | 123 | 0.280 |
Why?
|
| Osteoprotegerin | 2 | 2017 | 17 | 0.270 |
Why?
|
| Autoantibodies | 2 | 2018 | 112 | 0.260 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2017 | 27 | 0.260 |
Why?
|
| Carcinoma | 2 | 2019 | 106 | 0.250 |
Why?
|
| Epoxy Compounds | 2 | 2015 | 15 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 727 | 0.240 |
Why?
|
| Nutrition Assessment | 4 | 2020 | 79 | 0.240 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 25 | 0.240 |
Why?
|
| Myeloid Cells | 1 | 2025 | 31 | 0.230 |
Why?
|
| Hemoglobins | 2 | 2015 | 112 | 0.230 |
Why?
|
| Androgens | 2 | 2017 | 107 | 0.230 |
Why?
|
| Sterilization, Tubal | 1 | 2024 | 6 | 0.220 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2017 | 25 | 0.220 |
Why?
|
| Thyroid Neoplasms | 1 | 2025 | 49 | 0.220 |
Why?
|
| Genetic Testing | 1 | 2025 | 90 | 0.220 |
Why?
|
| Gallbladder Neoplasms | 1 | 2024 | 3 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 2 | 2016 | 120 | 0.210 |
Why?
|
| Contraceptives, Oral, Hormonal | 4 | 2017 | 14 | 0.200 |
Why?
|
| Inflammation | 4 | 2021 | 729 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 164 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 130 | 0.190 |
Why?
|
| Vitamin A | 1 | 2022 | 85 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 284 | 0.180 |
Why?
|
| Adolescent | 7 | 2025 | 5950 | 0.180 |
Why?
|
| Leptin | 1 | 2022 | 118 | 0.170 |
Why?
|
| Netherlands | 2 | 2022 | 12 | 0.170 |
Why?
|
| Adiposity | 1 | 2021 | 155 | 0.160 |
Why?
|
| Stromal Cells | 1 | 2019 | 54 | 0.160 |
Why?
|
| Smoking | 2 | 2024 | 1019 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 421 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 638 | 0.150 |
Why?
|
| Parturition | 1 | 2018 | 22 | 0.150 |
Why?
|
| Prolactin | 2 | 2017 | 64 | 0.150 |
Why?
|
| Neoplasms | 3 | 2017 | 1341 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 661 | 0.140 |
Why?
|
| Meat | 1 | 2018 | 46 | 0.140 |
Why?
|
| Population Surveillance | 2 | 2017 | 245 | 0.140 |
Why?
|
| Australia | 3 | 2025 | 95 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 680 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 228 | 0.140 |
Why?
|
| RANK Ligand | 1 | 2017 | 19 | 0.130 |
Why?
|
| Genotype | 3 | 2018 | 796 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 77 | 0.130 |
Why?
|
| Survival Rate | 2 | 2015 | 353 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 310 | 0.130 |
Why?
|
| Glioma | 1 | 2018 | 92 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 30 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 102 | 0.130 |
Why?
|
| Body Height | 1 | 2017 | 53 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 2803 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2016 | 4 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 3 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2016 | 25 | 0.120 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 26 | 0.120 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 28 | 0.120 |
Why?
|
| New England | 2 | 2013 | 18 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 59 | 0.120 |
Why?
|
| Male | 8 | 2025 | 22779 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 928 | 0.120 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 41 | 0.120 |
Why?
|
| Coronary Disease | 1 | 2016 | 123 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 933 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 502 | 0.120 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 16 | 0.120 |
Why?
|
| Epidemiologic Studies | 1 | 2015 | 33 | 0.110 |
Why?
|
| Diet Records | 1 | 2015 | 58 | 0.110 |
Why?
|
| Estrogens | 1 | 2016 | 202 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2016 | 201 | 0.110 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2014 | 5 | 0.110 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 18 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 187 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2017 | 548 | 0.110 |
Why?
|
| Cell Line, Transformed | 1 | 2013 | 96 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 138 | 0.100 |
Why?
|
| Powders | 1 | 2013 | 20 | 0.100 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2016 | 19 | 0.100 |
Why?
|
| Gene Expression | 1 | 2016 | 692 | 0.100 |
Why?
|
| Lactose | 1 | 2012 | 16 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 602 | 0.100 |
Why?
|
| Nurses | 1 | 2013 | 55 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 64 | 0.090 |
Why?
|
| BRCA1 Protein | 2 | 2025 | 58 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 350 | 0.090 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 37 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 78 | 0.090 |
Why?
|
| Hormones | 2 | 2024 | 56 | 0.090 |
Why?
|
| China | 2 | 2024 | 233 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 729 | 0.080 |
Why?
|
| Animals | 4 | 2025 | 16695 | 0.080 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 3 | 0.070 |
Why?
|
| Mice | 2 | 2025 | 6490 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2598 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 1554 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2019 | 362 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2017 | 95 | 0.070 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 58 | 0.070 |
Why?
|
| ROC Curve | 2 | 2017 | 157 | 0.060 |
Why?
|
| Maternal Age | 2 | 2018 | 34 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 3077 | 0.060 |
Why?
|
| Animal Migration | 1 | 2005 | 6 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 774 | 0.060 |
Why?
|
| Moths | 1 | 2005 | 13 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2017 | 34 | 0.060 |
Why?
|
| Malaysia | 1 | 2024 | 10 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2025 | 130 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2008 | 541 | 0.050 |
Why?
|
| Testosterone | 2 | 2017 | 211 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 456 | 0.050 |
Why?
|
| Work Schedule Tolerance | 1 | 2023 | 4 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2024 | 133 | 0.050 |
Why?
|
| Estradiol | 2 | 2017 | 269 | 0.050 |
Why?
|
| Japan | 1 | 2024 | 348 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 860 | 0.050 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 149 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 74 | 0.050 |
Why?
|
| Adipokines | 1 | 2022 | 25 | 0.050 |
Why?
|
| Adiponectin | 1 | 2022 | 59 | 0.050 |
Why?
|
| Sleep | 1 | 2023 | 179 | 0.050 |
Why?
|
| Carnitine | 1 | 2021 | 8 | 0.040 |
Why?
|
| Sphingomyelins | 1 | 2021 | 9 | 0.040 |
Why?
|
| Glycine | 1 | 2021 | 47 | 0.040 |
Why?
|
| Serine | 1 | 2021 | 81 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 90 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 1221 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 2111 | 0.040 |
Why?
|
| Microdissection | 1 | 2019 | 13 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 162 | 0.040 |
Why?
|
| Liver | 1 | 2021 | 503 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 88 | 0.040 |
Why?
|
| Testosterone Congeners | 1 | 2017 | 3 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 32 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 11 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 53 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 50 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2017 | 75 | 0.030 |
Why?
|
| Child | 1 | 2024 | 3381 | 0.030 |
Why?
|
| North America | 1 | 2016 | 85 | 0.030 |
Why?
|
| Herpes Genitalis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 115 | 0.030 |
Why?
|
| Herpesvirus 2, Human | 1 | 2016 | 9 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 139 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 49 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 352 | 0.030 |
Why?
|
| Intrauterine Devices | 1 | 2016 | 19 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 136 | 0.030 |
Why?
|
| Chlamydia trachomatis | 1 | 2016 | 69 | 0.030 |
Why?
|
| Term Birth | 1 | 2015 | 9 | 0.030 |
Why?
|
| Culture Media | 1 | 2015 | 96 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 256 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 147 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 64 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 91 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 136 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 386 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2015 | 97 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 725 | 0.030 |
Why?
|
| Gravidity | 1 | 2013 | 3 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 438 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 199 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 295 | 0.030 |
Why?
|
| Progesterone | 1 | 2013 | 120 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 661 | 0.020 |
Why?
|
| Mutation | 1 | 2017 | 1169 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2011 | 5 | 0.020 |
Why?
|
| Models, Biological | 1 | 2015 | 711 | 0.020 |
Why?
|
| Talin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Peritoneum | 1 | 2011 | 9 | 0.020 |
Why?
|
| Integrin alpha5beta1 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Myosin Type II | 1 | 2011 | 15 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 363 | 0.020 |
Why?
|
| Fibronectins | 1 | 2011 | 69 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 237 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 506 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 43 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 154 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2008 | 154 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 436 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 534 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 60 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2005 | 47 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 1416 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 594 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1848 | 0.010 |
Why?
|